Published in Nat Commun on March 09, 2017
The Sequence Alignment/Map format and SAMtools. Bioinformatics (2009) 232.39
BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics (2010) 53.23
Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics (2014) 44.23
GenePattern 2.0. Nat Genet (2006) 29.07
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol (2014) 27.48
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
STAR: ultrafast universal RNA-seq aligner. Bioinformatics (2012) 25.21
Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol (1992) 12.96
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics (2006) 10.83
Stromal gene expression predicts clinical outcome in breast cancer. Nat Med (2008) 10.68
Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol (2003) 8.61
CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 8.54
A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell (1992) 6.86
Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature (1992) 5.47
Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer (2012) 5.15
Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav. Mol Cell Biol (1994) 5.02
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science (2015) 4.88
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell (2010) 3.52
The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature (2014) 3.45
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov (2013) 3.25
An alternative to SH2 domains for binding tyrosine-phosphorylated proteins. Science (1994) 2.80
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell (2016) 2.65
Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on the EGF receptor-MAP kinase-fos signalling pathway. EMBO J (1997) 2.62
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat (2014) 2.61
Requirement for both Shc and phosphatidylinositol 3' kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis. Mol Cell Biol (1998) 2.48
DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. Cell (2015) 2.45
First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov (2012) 2.31
Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res (2011) 2.25
The Shc adaptor protein is highly phosphorylated at conserved, twin tyrosine residues (Y239/240) that mediate protein-protein interactions. Curr Biol (1996) 2.13
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature (2015) 1.98
ShcA signalling is essential for tumour progression in mouse models of human breast cancer. EMBO J (2008) 1.82
Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation. Cell Cycle (2011) 1.79
Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A (2011) 1.78
New role for Shc in activation of the phosphatidylinositol 3-kinase/Akt pathway. Mol Cell Biol (2000) 1.68
Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur J Immunol (2013) 1.63
STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas. Breast Cancer Res (2012) 1.56
Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci U S A (2015) 1.54
miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res (2013) 1.46
MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop. Sci Signal (2011) 1.42
STAT1 and STAT3 in tumorigenesis: A matter of balance. JAKSTAT (2012) 1.27
Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression. J Immunol (2011) 1.26
Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity. Cell (2015) 1.26
Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden. Neoplasia (2010) 1.23
The phosphotyrosine interaction domain of SHC recognizes tyrosine-phosphorylated NPXY motif. J Biol Chem (1995) 1.23
Combinatorial ShcA docking interactions support diversity in tissue morphogenesis. Science (2007) 1.20
STAT3 in immune responses and inflammatory bowel diseases. Cell Res (2006) 1.18
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity (2016) 1.11
Shc proteins are strong, independent prognostic markers for both node-negative and node-positive primary breast cancer. Cancer Res (2003) 1.09
Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells. J Biol Chem (2013) 1.06
Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity. Cancer Discov (2013) 1.00
The tumor suppressor function of STAT1 in breast cancer. JAKSTAT (2013) 1.00
CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells. J Clin Invest (2014) 0.96
Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines. Cell Death Differ (2013) 0.95
Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune response. Cancer Res (2010) 0.89
Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer. Breast Cancer Res Treat (2015) 0.88
Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling. Cell (2016) 0.87
A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer Immunol Res (2014) 0.87
ShcA tyrosine phosphorylation sites can replace ShcA binding in signalling by middle T-antigen. EMBO J (2001) 0.87
STAT1 drives tumor progression in serous papillary endometrial cancer. Cancer Res (2014) 0.86
STAT3 Establishes an Immunosuppressive Microenvironment during the Early Stages of Breast Carcinogenesis to Promote Tumor Growth and Metastasis. Cancer Res (2015) 0.85
Stat1 stimulates cap-independent mRNA translation to inhibit cell proliferation and promote survival in response to antitumor drugs. Proc Natl Acad Sci U S A (2015) 0.83
The ShcA adaptor activates AKT signaling to potentiate breast tumor angiogenesis by stimulating VEGF mRNA translation in a 4E-BP-dependent manner. Oncogene (2014) 0.82
Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. Blood (2014) 0.81
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. Nat Med (2016) 0.80
Increased STAT1 signaling in endocrine-resistant breast cancer. PLoS One (2014) 0.78
Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells. Sci Signal (2016) 0.77
The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness. J Cell Biochem (2016) 0.76